logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Aspergillosis

    FiltersReset Filters
    6 results

    • posaconazole

      (POSACONAZOLE)
      Camber Pharmaceuticals, Inc.
      Usage: Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in severely immunocompromised patients, such as those with graft-versus-host disease after hematopoietic stem cell transplant or prolonged neutropenia due to chemotherapy. It is approved for adults and pediatric patients aged 2 years and older.

    • posaconazole

      (posaconazole)
      Hikma Pharmaceuticals USA Inc.
      Usage: Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in high-risk immunocompromised patients, and for the treatment of oropharyngeal candidiasis, including cases refractory to itraconazole or fluconazole, in adults and pediatric patients 13 years and older.

    • posaconazole

      (posaconazole)
      Mylan Institutional LLC
      Usage: Posaconazole injection is indicated for treating invasive aspergillosis in patients aged 13 and older and for prophylaxis against invasive Aspergillus and Candida infections in severely immunocompromised patients, including those with graft-versus-host disease or prolonged neutropenia from chemotherapy, starting at age 2.

    • posaconazole

      (posaconazole)
      Novadoz Pharmaceuticals LLC
      Usage: Posaconazole delayed-release tablets are indicated for the prophylaxis of invasive Aspergillus and Candida infections in severely immunocompromised patients, including HSCT recipients with graft-versus-host disease and those with prolonged neutropenia from chemotherapy. It is suitable for adults and pediatric patients aged 2 years and older weighing over 40 kg.

    • sporanox

      (ITRACONAZOLE)
      Janssen Pharmaceuticals, Inc.
      Usage: SPORANOX (itraconazole) capsules are indicated for treating fungal infections in both immunocompromised and non-immunocompromised patients, including blastomycosis, histoplasmosis, and aspergillosis. It is also used for onychomycosis of toenails and fingernails due to dermatophytes in non-immunocompromised patients.

    • tolsura

      (Itraconazole)
      Mayne Pharma Commercial LLC
      Usage: TOLSURA is indicated for treating pulmonary and extrapulmonary blastomycosis, histoplasmosis (including chronic cavitary and disseminated forms), and pulmonary and extrapulmonary aspergillosis in both immunocompromised and non-immunocompromised adults who cannot tolerate or are refractory to amphotericin B therapy. It is not for onychomycosis treatment.